Jun 27, 2022 / 12:00PM GMT
Operator
Hello, and welcome to Ipsen's conference call and webcast to the acquisition of Epizyme Inc. The call is being hosted by David Loew, Chief Executive of Ipsen. (Operator Instructions)
It is now my pleasure to turn today's call over to David Loew. Please go ahead.
David Loew - Ipsen S.A. - MD, CEO & Director
Good afternoon or good morning, everyone. As you've just heard, I'm David Loew, Chief Executive Officer of Ipsen. I'm delighted that you have joined today as we take you through today's exciting news on the acquisition of Epizyme.
Please turn to Slide 2. This is our usual safe harbor statement, which outlines the routine risks and uncertainties contained within this presentation.
Please turn to Slide 3. I'm joined today by Howard Mayer, Ipsen's Head of Research and Development, as well as our CFO, Aymeric Le Chatelier. We'll provide a brief presentation before using the majority of the time to answer your questions.
Please turn to Slide 4. I will begin the presentation by taking you through the strategic rationale for
Ipsen SA to Acquire Epizyme Inc Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot